Biohaven Licenses Kv7 Platform And Epilepsy Candidate Opakalim To SK Biopharmaceuticals In Deal Worth Up To $795M, Biohaven To Receive $400M Upfront | 웨이프 WAPE
뉴스벤징가
Biohaven Licenses Kv7 Platform And Epilepsy Candidate Opakalim To SK Biopharmaceuticals In Deal Worth Up To $795M, Biohaven To Receive $400M Upfront
댓글 —
댓글을 불러오고 있어요…